{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:46:52Z","timestamp":1791899212548,"version":"4.3.4"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The management strategies for\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                    <\/jats:styled-content>\n                    treatment are still diverse, especially because of the unequal availability of the drugs needed. In addition, the development of resistance to some antibiotics leads to unsatisfactory results. The role of\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>H. pylori<\/jats:italic>\n                    <\/jats:styled-content>\n                    in gastric cancer, which allows the possibility of prevention in the general population by eradicating the bacteria, is a stimulus to have well\u2010established regimens. This article presents the antimicrobial stewardship principles that can guarantee appropriate treatment. The optimization of the clarithromycin\u2010based triple therapy includes antimicrobial susceptibility testing for clarithromycin, a higher dose of amoxicillin than in the original regimen, more than twice a day, and a proton pump inhibitor (PPI) like rabeprazole or esomeprazole, all administered for 2\u2009weeks. The other regimen often used, the bismuth quadruple therapy, is optimal with the 3\u2010in\u20101 capsule and a standard or high dose of PPI. In all cases, an eradication control must be performed after 4 to 6\u2009weeks. The so\u2010called concomitant treatment does not meet stewardship principles. The availability of Potassium\u2010Competitive Acid Blockers (P\u2010CABs) in some countries could allow the use of a dual therapy with only amoxicillin, but it must be confirmed by proper trials in Western countries.\n                  <\/jats:p>","DOI":"10.1111\/hel.70158","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:16Z","timestamp":1791896176000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management Strategies for\n                    <i>Helicobacter pylori<\/i>\n                    \u2014Application of the Stewardship Principles"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-1612","authenticated-orcid":false,"given":"Francis","family":"Megraud","sequence":"first","affiliation":[{"name":"INSERM U1312 BRIC Team 4 University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bess\u00e8de","sequence":"additional","affiliation":[{"name":"INSERM U1312 BRIC Team 4 University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Matysiak\u2010Budnik","sequence":"additional","affiliation":[{"name":"IMAD, Hepato\u2010Gastroenterology &amp; Digestive Oncology University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022","volume":"166","author":"Chen Y. C.","year":"2024","journal-title":"Gastroenterology"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1080\/00365520500390402","article-title":"Spotlight on Gastroenterology \u2010 The Nobel Prize Laureates in Physiology or Medicine 2005: John Robin Warren and Barry James Marshall","volume":"40","author":"Hellstr\u00f4m P. M.","year":"2005","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"e_1_2_8_4_1","volume-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","author":"Schistosomes, liver flukes and Helicobacter pylori","year":"1994"},{"key":"e_1_2_8_5_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray F.","year":"2024","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto Global Consensus Report on Helicobacter pylori Gastritis","volume":"64","author":"Sugano K.","year":"2015","journal-title":"Gut"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMsb2515372","article-title":"Helicobacter pylori Screen and Treat Programs for Gastric Cancer Prevention \u2013 IARC Working Group Report","volume":"394","author":"Park J. Y.","year":"2026","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70063","article-title":"Helicobacter pylori Infection in Children Versus Adults, Differences in Management Guidelines: Risks and Benefits of Treatment in Childhood","volume":"30","author":"Homan M.","year":"2025","journal-title":"Helicobacter"},{"issue":"5","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.ajic.2006.05.237","article-title":"Antimicrobial Stewardship","volume":"34","author":"Fishman N.","year":"2006","journal-title":"American Journal of Infection Control"},{"key":"e_1_2_8_10_1","volume-title":"Population\u2010Based Helicobacter pylori Screen\u2010And\u2010Treat Strategies for Gastric Cancer Prevention: Guidance on Implementation","author":"Moayyedi P.","year":"2025"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211064080","article-title":"Helicobacter Diagnosis and Therapy in the Era of Antimicrobial Stewardship","volume":"14","author":"Shiotani A.","year":"2021","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411708","article-title":"Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection","volume":"24","author":"Ng H. Y.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/pharma3010006","article-title":"Crises in Antimicrobial Stewardship: Misuse of Clarithromycin for Helicobacter pylori Therapy","volume":"3","author":"Graham D. Y.","year":"2024","journal-title":"Pharmacoepidemiology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70013","article-title":"Managing Helicobacter pylori as an Infectious Disease: Implementation of Antimicrobial Stewardship","volume":"30","author":"Hsu J. Y.","year":"2025","journal-title":"Helicobacter"},{"key":"e_1_2_8_15_1","first-page":"130","article-title":"Efficacy and Tolerability of a Short Term, Low Dose Triple Therapy for Eradication of Helicobacter pylori","volume":"56","author":"Bazzoli F.","year":"1993","journal-title":"Acta Gastro\u2010Enterologica Belgica"},{"key":"e_1_2_8_16_1","first-page":"140","article-title":"Amoxicillin\u2010Clarithromycin\u2010Omeprazole: The Best Therapy for Helicobacter pylori Infection?","volume":"56","author":"Lamouliatte H.","year":"1993","journal-title":"Acta Gastro\u2010Enterologica Belgica"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0016-5085(99)70119-8","article-title":"The MACH2 Study: Role of Omeprazole in Eradication of Helicobacter pylori With 1\u2010Week Triple Therapies","volume":"116","author":"Lind T.","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/00365529509090281","article-title":"Helicobacter Pylori and Peptic Ulcer","volume":"210","author":"Korman M. G.","year":"1995","journal-title":"Scandinavian Journal of Gastroenterology. Supplement"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/00042737-199512000-00011","article-title":"Quadruple Therapy Compared With Dual Therapy for Eradication of Helicobacter pylori in Ulcer Patients: Results of a Randomized Prospective Single\u2010Centre Study","volume":"7","author":"de Boer W. A.","year":"1995","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"10","key":"e_1_2_8_20_1","first-page":"53","article-title":"Eradication Therapies for Helicobacter pylori","volume":"33","author":"Borody T. J.","year":"1998","journal-title":"Journal of Gastroenterology"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current Concepts in the Management of Helicobacter pylori Infection: The Maastricht III Consensus Report","volume":"56","author":"Malfertheiner P.","year":"2007","journal-title":"Gut"},{"key":"e_1_2_8_22_1","volume-title":"WHO Global Strategy for Containment of Antimicrobial Resistance","year":"2011"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic\u2010Resistant Bacteria and Tuberculosis","volume":"18","author":"Tacconelli E.","year":"2018","journal-title":"Lancet Infectious Diseases"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/JCM.41.1.397-402.2003","article-title":"Real\u2010Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in Helicobacter pylori","volume":"41","author":"Oleastro M.","year":"2003","journal-title":"Journal of Clinical Microbiology"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12855","article-title":"Adaptation of an In\u2010House PCR for the Detection of Helicobacter Pylori and the Mutations Associated With Macrolide Resistance Into Ready\u2010To\u2010Use PCR Microwell Strips","volume":"26","author":"B\u00e9n\u00e9jat L.","year":"2021","journal-title":"Helicobacter"},{"key":"e_1_2_8_26_1","first-page":"469","article-title":"Helicobacter pylori Antimicrobial Resistance and the Role of Next\u2010Generation Sequencing","volume":"20","author":"Andrews C. B.","year":"2024","journal-title":"Gastroenterology & Hepatology"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101217","article-title":"Genomic Determinants of Antimicrobial Resistance for Helicobacter pylori Treatment: A Retrospective Phenotypic and Genotypic Observational Study","volume":"7","author":"Martinez\u2010Martinez F. J.","year":"2026","journal-title":"Lancet Microbe"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70029","article-title":"First \u2010Line Therapy for Helicobacter pylori Therapy in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management","volume":"30","author":"Tepes B.","year":"2025","journal-title":"Helicobacter"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.3748\/wjg.v25.i34.5097","article-title":"Optimizing Proton Pump Inhibitors in Helicobacter pylori Treatment: Old and New Tricks to Improve Effectiveness","volume":"25","author":"Ierardi E.","year":"2019","journal-title":"World Journal of Gastroenterology"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.12998\/wjcc.v9.i1.133","article-title":"Polymerase Chain Reaction\u2010Based Tests for Detecting Helicobacter pylori Clarithromycin Resistance in Stool Samples: A Meta\u2010Analysis","volume":"9","author":"Gong R. J.","year":"2021","journal-title":"World Journal of Clinical Cases"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(95)90524-3","article-title":"Non\u2010Endoscopic Method to Obtain Helicobacter pylori for Culture","volume":"345","author":"Perez\u2010Trallero E.","year":"1995","journal-title":"Lancet"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12773","article-title":"Classification System for Helicobacter pylori Therapies: Compared and Contrasted to Traditional Infectious Disease Therapy","volume":"26","author":"Graham D. Y.","year":"2021","journal-title":"Helicobacter"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14787210.2018.1511427","article-title":"Understanding Treatment Guidelines With Bismuth and Non\u2010Bismuth Quadruple Helicobacter pylori Eradication Therapies","volume":"16","author":"Graham D. Y.","year":"2018","journal-title":"Expert Review of Anti\u2010Infective Therapy"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults","volume":"151","author":"Fallone C. A.","year":"2016","journal-title":"Gastroenterology"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"119","author":"Chey W. D.","year":"2024","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1111\/bcp.14739","article-title":"Pharmacokinetics of Amoxicillin in Obese and Nonobese Subjects","volume":"87","author":"Soares A. L.","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/dkf219","article-title":"In Vitro Transfer of Clarithromycin and Amoxicillin Across the Epithelial Barrier: Effect of Helicobacter pylori","volume":"50","author":"Matysiak\u2010Budnik T.","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ueg2.12476","article-title":"Role of Proton Pump Inhibitors Dosage and Duration in Helicobacter pylori Eradication Treatment: Results From the European Registry on H. pylori Management","volume":"12","author":"Pabon\u2010Carrasco M.","year":"2024","journal-title":"United European Gastroenterology Journal"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/08850666241245364","article-title":"Intravenous Antibiotics in the Management of H. pylori Infection: A Systematic Review","volume":"40","author":"Chau Y. L. A.","year":"2025","journal-title":"Journal of Intensive Care Medicine"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/gutjnl-2024-332804","article-title":"Evolution of the Use, Effectiveness and Safety of Bismuth\u2010Containing Quadruple Therapy for Helicobacter pylori Infection Between 2013 and 2021: Results From the European Registry on H. pylori Management (Hp\u2010EuReg)","volume":"74","author":"Olmedo L.","year":"2024","journal-title":"Gut"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00042737-200012060-00009","article-title":"Comparison of Tests for Assessment of Helicobacter pylori Eradication: Results of a Multi\u2010Centre Study Using Centralized Facility Testing","volume":"12","author":"Megraud F.","year":"2000","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"e_1_2_8_42_1","first-page":"CD012080","article-title":"Non\u2010Invasive Diagnostic Tests for Helicobacter pylori Infection","volume":"3","author":"Best L. M.","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium\u2010Competitive Acid Blockers: Current Clinical Use and Future Developments","volume":"26","author":"Scarpignato C.","year":"2024","journal-title":"Current Gastroenterology Reports"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.102768","article-title":"The Efficacy and Safety of Vonoprazan\u2010Based High\u2010Dose Dual Therapy for Eradication of Helicobacter pylori: A Systematic Review and Meta\u2010Analysis","volume":"18","author":"Zhang M. M.","year":"2025","journal-title":"Journal of Infection and Public Health"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial","volume":"163","author":"Chey W. D.","year":"2022","journal-title":"Gastroenterology"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.14309\/ajg.0000000000003084","article-title":"Comparative Efficacy and Safety of Potassium\u2010Competitive Acid Blockers\u2010Based Dual, Triple, and Quadruple Regimens for First\u2010Line Helicobacter pylori Treatment: A Systematic Review and Network Meta\u2010Analysis","volume":"120","author":"Rokkas T.","year":"2025","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/apt.13214","article-title":"Systematic Review With Meta\u2010Analysis: Saccharomyces Boulardii Supplementation and Eradication of Helicobacter pylori Infection","volume":"41","author":"Szajewska H.","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"e_1_2_8_48_1","article-title":"Vonoprazan\u2010Amoxicillin Dual Therapy With or Without Saccharomyces Boulardii Supplementation as a Rescue Regimen for Helicobacter pylori Infection","volume":"19","author":"Qu D. N.","year":"2026","journal-title":"Infection and Drug Resistance"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.70158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hel.70158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.70158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:23Z","timestamp":1791896183000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hel.70158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/hel.70158"],"URL":"https:\/\/doi.org\/10.1111\/hel.70158","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70158"}}